[通过皮肤试验证明对辉瑞 - 生物科技公司疫苗过敏]
[Allergy to Pfizer-BioNTech® vaccine demonstrated by skin testing].
作者信息
Estrada-García Carlos David, Macías-Robles Ana Paola, Cortés-Grimaldo Rosa María, Carvajal-Alonso Hilda Lilian, Barreto-Alcalá Marlen, Ramírez-Nepomuceno Adriana, Esparza-Amaya David, Coronado-Hernández Kareli Guadalupe, Barrios-Díaz Britza, Campos-Téllez Héctor Hugo
机构信息
Residente de primer año de Alergia e Inmunología.
Médico adscrito y profesora titular de la sub-especialidad en Alergia e Inmunología Clínica Pediátrica.
出版信息
Rev Alerg Mex. 2023 Jan 4;69(2):89-92. doi: 10.29262/ram.v69i2.1088.
BACKGROUND
The Pfizer-BioNTech® BNT162b2 vaccine, provides 95% effectiveness from the second dose onwards. The reported rate of anaphylaxis to COVID-19 vaccines is 4.7 cases/million doses administered.
CASE REPORT
30-year-old female, health professional, history of allergic rhinitis, asthma, reaction to eye cosmetics and adhesive tape: erythema, edema, and local pruritus. Immediately after application of the first dose of Pfizer-BioNTech vaccine, she presented grade III anaphylaxis. The patient was stratified, phenotyped and skin tests with PEG 3350 were positive. A recommendation was issued not to reapply vaccine containing polyethylene glycol and alternatives were offered.
CONCLUSIONS
An adequate risk stratification should be performed before applying mRNA-based COVID-19 vaccines for the first time in at-risk groups. In case of anaphylaxis at the first dose, phenotyping and further study with PEG skin tests should be performed and vaccination alternatives should be offered.
背景
辉瑞-生物科技公司的BNT162b2疫苗从第二剂起提供95%的有效性。报告的新冠病毒疫苗过敏反应发生率为每接种100万剂有4.7例。
病例报告
一名30岁的女性卫生专业人员，有过敏性鼻炎、哮喘病史，对眼部化妆品和胶带过敏：出现红斑、水肿和局部瘙痒。在接种第一剂辉瑞-生物科技疫苗后，她立即出现III级过敏反应。对该患者进行了分层、表型分析，聚乙二醇3350皮肤试验呈阳性。已发布建议，不要再接种含聚乙二醇的疫苗，并提供了替代方案。
结论
在对高危人群首次接种基于信使核糖核酸的新冠病毒疫苗之前，应进行充分的风险分层。如果在第一剂时出现过敏反应，应进行表型分析并使用聚乙二醇皮肤试验进行进一步研究，并提供替代疫苗接种方案。
Zotero 插件